Google still trailing ADD drug maker in IPO

Google's stock has amazed investors and the public, but the returns still lag those experienced by , a 19-employee company that has designed an attention deficit disorder drug.

The two companies went public two weeks apart in 2004. New River went public at $8.00 and is now sells at above $33, giving it a 317% return, according to statistics on IPO Home. Google went out at $85 and sells for $286, a 236 percent return. Google also trails China's Shanda Interactive, which has seen its stock rise from $11 to $38, in terms of return.

It's an improvement for the search giant, however. In April, it also trailed WPT Enterprises, which organizes the world poker tournament, and Syneron Medical, an Israeli company specializing in laser hair removal technology.

Tags:
Tech Culture
About the author

    Michael Kanellos is editor at large at CNET News.com, where he covers hardware, research and development, start-ups and the tech industry overseas.

     

    Discuss Google still trailing ADD drug maker in IPO

    Conversation powered by Livefyre

    Show Comments Hide Comments
    Latest Articles from CNET
    Low Latency 124: Whack-a-Meerkat